聯環藥業(600513.SH):獲得藥物臨牀試驗批準通知書
格隆匯7月18日丨聯環藥業(600513.SH)公佈,公司於近日收到國家藥品監督管理局覈準簽發的關於瑞盧戈利片的《藥物臨牀試驗批準通知書》,現已正式取得瑞盧戈利片(簡稱“本品”)開展前列腺癌臨牀試驗的批準,並將於近期就本品開展“評價瑞盧戈利片治療雄激素敏感性進展期前列腺癌的有效性和安全性的Ⅲ期多中心臨牀試驗”。瑞盧戈利片是一種促性腺激素釋放激素(GnRH)受體拮抗劑,主要用於治療前列腺癌和子宮內膜異位症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.